Thumbnail Image
Publication

Postprogression outcomes in patients with ovarian carcinoma associated with amutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3

O'Malley, D. M.
; 
Oza, A. M.
; 
Lorusso, D.
; 
Aghajanian, C.
; 
Oaknin, A.
; 
Dean, A.
; 
Colombo, N.
; 
Weberpals, J. I.
; 
Clamp, Andrew R
; 
Scambia, G.
... show 10 more
Citations
Altmetric:
Abstract
In the ARIEL3 study (NCT01968213), rucaparib maintenance treatment significantlyimproved progression-free survival (PFS) versus placebo in all predefined, nestedcohorts ( BRCA mutant; BRCA mutant + wildtype BRCA/high loss of heterozygosity; and intent-to-treat population). Here we analyzed postprogressionoutcomes to evaluate the durability of the clinical benefit of rucaparib maintenancetreatment following disease progression in the subgroup of patients with tumors associatedwith a mutation in a prespecified, non- BRCA, homologous recombination repair (HRR) gene.
Authors
O'Malley, D. M.
Oza, A. M.
Lorusso, D.
Aghajanian, C.
Oaknin, A.
Dean, A.
Colombo, N.
Weberpals, J. I.
Clamp, Andrew R
Scambia, G.
Leary, A.
Holloway, R. W.
Gancedo, M. A.
Fong, P. C.
Goh, J. C.
Armstrong, D. K.
Banerjee, S.
Garcia-Donas, J.
Swisher, E. M.
Cameron, T.
Maloney, L.
Goble, S.
Lin, K. K.
Ledermann, J. A.
Coleman, R. L.
Affiliation
The Ohio State University, James Cancer Hospital, Columbus, OH, USA
Description
Date
2020
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3. Gynecologic Oncology. 2020;159:74-5.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/623506
Embedded videos